ijms-logo

Journal Browser

Journal Browser

Molecular Oncogenetics: Insights into Cancer Development, Drug Resistance, and Personalized Treatments

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 20 November 2024 | Viewed by 817

Special Issue Editors

Special Issue Information

Dear Colleagues,

This Special Issue, entitled “Molecular Oncogenetics: Insights into Cancer Development, Drug Resistance, and Personalized Treatments”, aims to bring together cutting-edge research and reviews that explore the complex interplay of genetic and molecular alterations driving cancer progression and therapy resistance. This Special Issue will provide a comprehensive platform for the latest discoveries in oncogenetics, with a focus on the genomic and transcriptomic landscapes that underpin cancer development, hereditary cancer syndromes, and the mechanisms of drug resistance.

We invite submissions that delve into the molecular alterations and oncogenetic mechanisms influencing cancer cell behavior and patient outcomes. Studies that leverage genomic and transcriptomic data to unravel the genetic landscape of cancer and identify biomarkers for early detection and prognosis are particularly welcome. Additionally, we seek research that investigates the molecular basis of drug resistance, aiming to uncover novel therapeutic targets and strategies to overcome resistance.

A key focus of this Special Issue will be on personalized cancer treatments, where insights from oncogenetics are applied to tailor therapies to individual patient profiles. We encourage contributions that demonstrate the application of molecular oncogenetics in developing precision medicine approaches, including the design of personalized treatment regimens based on genetic and molecular profiling. This Special Issue is supervised by Prof. Dr. Daniela Calina and Dr. Luca Falzone, assisted by Guest Editor Assistant Dr. Graziana Spoto (Humanitas Hospital of Catania; University of Catania, Italy).

Prof. Dr. Daniela Calina
Dr. Luca Falzone
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • oncogenetics
  • molecular alterations
  • genomics
  • transcriptomics
  • hereditary cancer syndromes
  • drug resistance mechanisms
  • tailored treatments
  • next-generation sequencing

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

29 pages, 3725 KiB  
Review
Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer
by Patrycja Gralewska, Arkadiusz Gajek, Agnieszka Marczak and Aneta Rogalska
Int. J. Mol. Sci. 2024, 25(15), 8304; https://doi.org/10.3390/ijms25158304 - 30 Jul 2024
Viewed by 642
Abstract
The current focus of ovarian cancer (OC) research is the improvement of treatment options through maximising drug effectiveness. OC remains the fifth leading cause of cancer-induced mortality in women worldwide. In recent years, nanotechnology has revolutionised drug delivery systems. Nanoparticles may be utilised [...] Read more.
The current focus of ovarian cancer (OC) research is the improvement of treatment options through maximising drug effectiveness. OC remains the fifth leading cause of cancer-induced mortality in women worldwide. In recent years, nanotechnology has revolutionised drug delivery systems. Nanoparticles may be utilised as carriers in gene therapy or to overcome the problem of drug resistance in tumours by limiting the number of free drugs in circulation and thereby minimising undesired adverse effects. Cell surface receptors, such as human epidermal growth factor 2 (HER2), folic acid (FA) receptors, CD44 (also referred to as homing cell adhesion molecule, HCAM), and vascular endothelial growth factor (VEGF) are highly expressed in ovarian cancer cells. Generation of active targeting nanoparticles involves modification with ligands that recognise cell surface receptors and thereby promote internalisation by cancer cells. Several poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) are currently used for the treatment of high-grade serous ovarian carcinomas (HGSOC) or platinum-sensitive relapsed OC. However, PARP resistance and poor drug bioavailability are common challenges, highlighting the urgent need to develop novel, effective strategies for ovarian cancer treatment. This review evaluates the utility of nanoparticles in ovarian cancer therapy, with a specific focus on targeted approaches and the use of PARPi nanocarriers to optimise treatment outcomes. Full article
Show Figures

Figure 1

Back to TopTop